drugset
drugset / Trial / NCT01429116

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

NCT01429116 ↗

Phase 3 Completed 200 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.

Timeline

Start
2011-10
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule 20 mg Oral

Indications

non-24-hour sleep-wake syndrome